Question explored with the scientific record
What’s the latest evidence on the efficacy and best programme for rTMS maintenance therapy?
The short version: the retrieved evidence does not answer your question. It has no trial of maintenance rTMS, no head-to-head comparison of maintenance schedules, and no long-term relapse data.
The records that surfaced are about acute rTMS, not maintenance. One review reports remission rates falling after a course of treatment: 75.3% at 2 months, 60% at 3 months, 42.7% at 4 months, and 22.6% at 6 months in 204 patients followed over years [2]. That is a decay curve, not a maintenance protocol, and it tells you relapse is common after stopping. A small study of 13 rTMS responders given citalopram afterward found 4 relapsed over 9 weeks [1]. That is continuation with a drug, not maintenance rTMS.
| Finding | What it shows | What it does not show |
|---|---|---|
| 204 patients, years of follow-up [2] | Remission falls to 22.6% by 6 months | Any maintenance schedule |
| 13 responders on citalopram [1] | 4 of 13 relapsed in 9 weeks | Maintenance rTMS |
| One bipolar case, weekly rTMS [3] | 2.5 years remission, one patient | Anything generalizable |
The only maintenance rTMS in these records is a single case report: a man with treatment-resistant bipolar disorder kept in remission for 2.5 years on weekly rTMS plus high-dose levothyroxine, lurasidone, and lithium [3]. One patient on four treatments proves nothing about the rTMS schedule. The fibromyalgia trial is about acute pain dosing, not maintenance, and sham stimulation also improved symptoms [4].
What this retrieval cannot see: any randomized trial comparing scheduled maintenance rTMS against stopping, any dose-finding study for interval or taper, and any long-term safety data. Those are the studies that would settle your question, and they are not here.
My call: there is no evidence here to name a best maintenance programme, and the decay data [2] is the strongest signal that some form of continuation matters. Confidence: not clear.
Sources used 4
-
Citalopram for Continuation Therapy After Repetitive Transcranial Magnetic Stimulation in Vascular Depression
This study investigates the effectiveness of citalopram as continuation therapy after repetitive transcranial magnetic stimulation (rTMS) in patients with vascular depression, revealing a 30.8% relapse rate among responders during a 9-week follow-up.
DOI: 10.1097/JGP.0b013e3181a88423 -
The Emerging Use of Brain Stimulation Treatments for Psychiatric Disorders
This paper provides a comprehensive review of current and emerging brain stimulation techniques for psychiatric disorders, detailing noninvasive methods (rTMS, tDCS, LFMS, T-PEMF, MST, FEAST, ECS) and invasive approaches (VNS, deep brain stimulation, DBS), evaluating their effic…
DOI: 10.3109/00048674.2011.615294 -
High dose Levothyroxine in combination with transcranial magnetic stimulation for the treatment of severe resistant subthreshold rapid cycling bipolar disorder; A case report
In a treatment-resistant rapid-cycling bipolar I patient with subthreshold symptoms, combined high-dose levothyroxine, rTMS, lurasidone, and lithium was followed by full remission by 7 months and maintenance for 2.5 years.
DOI: 10.17352/apt.000044 -
Is high-frequency repetitive transcranial magnetic stimulation of the left primary motor cortex superior to the stimulation of the left dorsolateral prefrontal cortex in fibromyalgia syndrome?
A randomized, double-blind, three-arm trial in 30 female fibromyalgia patients comparing 10 Hz rTMS over left primary motor cortex (M1) vs left dorsolateral prefrontal cortex (DLPFC) vs sham showed that active stimulation improved pain, fatigue, QoL, and depression, with M1 givi…
DOI: 10.1080/08990220.2019.1587400